Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate
F1000Research · 2023
DOI: 10.12688/f1000research.128116.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2023. Verfasst von Darmadi Darmadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Tenofovir, Hepatitis B virus, DNA, Viral. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF).
Methods
A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for 24 weeks at H. Adam Malik and USU Hospitals in Medan, Indonesia. The history of the samples was obtained, followed by physical examination, and blood collection. CTLA-4 polymorphism examination was carried out using real-time PCR, while the serum CTLA-4 levels were assessed with ELISA.
Results
The CTLA-4 -1661G>A polymorphism, genotype GG+AG, increased 1.52 times risk of not achieving HBV DNA suppression to TDF compared to genotype AA (p=0.041). High CTLA-4 levels increased 2.28 times risk, high HBV DNA levels increased 2.09 times risk, low ALT levels increased 1.95 times risk of not achieving HBV DNA suppression (p= 0.009, 0.026, 0.036, respectively). There was no relationship between gender, age, ethnicity, obesity, baseline AST, HBeAg, genotype, liver fibrosis and HBV DNA suppression after 24 weeks of treatment (p>0.05).
Conclusions
The levels of CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G>A polymorphism have a potential relationship with the suppression of HBV DNA in chronic hepatitis B patients with TDF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
- Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
- Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
- Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
- Master Program in Tropical Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia.
ORCID-Profile: Darmadi Darmadi, Tri Widyawati, Fauzi Yusuf
Zitieren
APA
Darmadi, D., Lindarto, D., Siregar, J., Widyawati, T., Rusda, M., Amin, M. M., Yusuf, F., Eyanoer, P. C., Lubis, M., & Rey, I. (2023). Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate. F1000Research. https://doi.org/10.12688/f1000research.128116.2
Vancouver
Darmadi D, Lindarto D, Siregar J, Widyawati T, Rusda M, Amin MM, et al. Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate. F1000Research. 2023. doi:10.12688/f1000research.128116.2
BibTeX
@article{Darmadi2023,
author = {Darmadi, Darmadi and Lindarto, Dharma and Siregar, Jelita and Widyawati, Tri and Rusda, Muhammad and Amin, Mustafa Mahmud and Yusuf, Fauzi and Eyanoer, Putri Chairani and Lubis, Masrul and Rey, Imelda},
title = {Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate},
journal = {F1000Research},
year = {2023},
doi = {10.12688/f1000research.128116.2}
}
EUVIMED